In this study, we present evidence that gene transfer of the CD40-ligand (CD154) into human immature dendritic cells (DC) imparts direct antitumor effects on tumor cells. DC infected with adenovirus directed to express human CD154 on the cell surface (CD154-DC) elicited significantly higher levels of immune accessory molecules commonly found on mature DC. We found that co-cultivation with a human squamous cell carcinoma cell line (OSC-70) with CD154-DC significantly inhibited cell growth. We further demonstrate that OSC-70 cells stimulated with CD154-DC were more susceptible to apoptosis via TNF-related apoptosis inducing ligand (TRAIL). Importantly, tumor cells co-cultured with CD154-DC in transwell plates expressed upregulated cell surface TRAIL-R2. CD154-DC produced higher levels of interferon (IFN)-g, IL-12p70 and soluble CD154, but the ability of CD154-DC to inhibit tumor cell growth was significantly abrogated by a neutralizing antibody to IFN-g, indicating that this was mainly mediated by IFN-g. Furthermore, intratumoral injection of CD154-DC significantly suppressed OSC-70 tumor growth in a xenograft model. Overall, these results reveal that CD154-DC have potential as an anti-cancer therapy by producing IFN-g to arrest adjacent tumor cell growth and increase the susceptibility of apoptosis via TRAIL.
Introduction
Dendritic cells (DC) are the most potent of antigen presenting cells and play a central role in the induction of the innate immune response. It is well known that DC show an important role for tumor elimination followed by the activation of cytotoxic T cells (CTL). 1 In addition to the generation of tumor-specific CTL, recent studies have shown that DC have a direct antitumor effect and activate the innate immune system. In one report, human monocytes and DC stimulated with interferon (IFN)-a or IFN-g produced cytotoxic effects on tumor cells through the TRAIL pathway. 2, 3 Another study demonstrated that human monocyte-derived DC stimulated with CD154 induced tumor necrosis factor (TNF)-a production that, in part, mediated the cytotoxic effects on tumor cells. 4 Finally, it was reported that IFN-g-stimulated DC or soluble factors secreted from lipopolysaccharide (LPS)-stimulated DC inhibited tumor cell growth. 5 While much evidence clearly defines an important role for DC in eliminating tumor cells, the mechanisms behind these direct antitumor effects are not entirely clear.
Activation of DC for the subsequent induction of antigen-specific T-cell responses and cytokine production requires CD40 ligation. However, DC in various maturation stages can produce cytokines in response to different stimuli. CD154-stimulated DC can secrete high amounts of interleukin-12 (IL-12), which is essential for the activation of T cells and natural killer (NK) cells by DC. 6 Precursor DC have the ability to produce type 1 IFNs, 7, 8 and those activated by viral infection can produce higher amounts that activate NK cells and macrophages. Further, murine macrophages and lymphoid DC stimulated with IL-12 or IL-18 have been shown to produce IFN-g. [9] [10] [11] [12] While IFN-g can regulate some apoptotic events and was shown recently to be a major modulator of death inducing stimuli such as TRAIL, there are no reports that CD154-stimulated DC can produce IFNs.
In the present study, we evaluated the antitumor effects of DCs transduced with the human CD154 gene (CD154-DC) on a co-cultured human squamous cell carcinoma cell line, OSC-70. In both mixed co-cultures and transwell co-cultures, tumor cell growth was suppressed. Further, cell death was induced strongly by TRAIL without direct contact by CD154-DC. We have demonstrated that significantly higher amounts of IFN-g were produced in culture supernatants of CD154-DC, and it was critical factor for CD154-DC-mediated tumor growth suppression. Consequently, antitumor therapeutic potential of CD154-DC was investigated.
Results

Phenotypic alterations of dendritic cells transduced with CD154
Adenovirus-infected DC were evaluated for the expression of various DC-lymphocyte co-stimulatory molecules by flow cytometry and by morphologic changes via photomicroscopy. In contrast to immature DC (im-DC) or DC transduced with lacZ (LacZ-DC), DC transduced with CD154 (CD154-DC) expressed high levels of CD154 as a transgene following CD80, CD83 and CD86 as DC maturation/activation markers ( Figure 1a ). CD154-DC strongly attached to the culture dish and were altered in morphology with respect to spindle shape and dendritic shape ( Figure  1b ). These data indicate that adenovirus encoding human CD154 is effective in inducing DC maturation and activation. ) significantly suppressed the growth of OSC-70 cells to 50.6 ± 1.2% (Figure 2a , n ¼ 3, Po0.05). Furthermore, the low DC to OSC-70 ratio of 1:8 was still effective in suppressing tumor growth in vitro.
To determine whether the growth inhibitory effect by CD154-DC was caused through DC-tumor cell interaction, OSC-70 cells were co-cultured with DC in a dualchamber transwell plate separated by a 0.4-mm pore size semi-permeable membrane. As shown in Figure 2b , the cell growth of OSC-70 cells co-cultured with CD154-DC (2 Â 10 5 ) in a transwell plate were suppressed to similar levels as the mixed co-cultivation (51.4±1.5%, n ¼ 3, Po0.05). These results indicate that the tumor growth inhibitory effect induced by CD154-DC could be caused by soluble factors secreted from DC and that it was independent of DC-tumor cell contact.
CD154-DC upregulated the TRAIL susceptibility of tumor cells
To investigate whether CD154-DC can alter the susceptibility to apoptosis inducing stimuli on co-cultured tumor cells, we analyzed the TRAIL-mediated apoptosis of tumor cells following co-cultivation with CD154-DC. We first examined the viability of CD154-DC co-cultured OSC-70 cells after treatment with recombinant TRAIL. As shown in Figure 3a , the viability of OSC-70 cells cocultured with CD154-DC compared to LacZ-DC was significantly decreased after treatment with recombinant TRAIL in a dose-dependent manner (n ¼ 3, Po0.05 for all concentrations of TRAIL used).
To assess another indicator of apoptosis, we next examined DNA fragmentation of CD154-DC co-cultured OSC-70 cells using the Br-dUTP uptake assay. The percentage of cells containing fragmented DNA after treatment with recombinant TRAIL following co-cultivation with CD154-DC was increased 10-fold as compared to controls (Figure 3b ).
CD154-DC induced surface antigen molecules on tumor cells
Expression levels of TRAIL-R1 (DR4) and TRAIL-R2 (DR5) are important to induce TRAIL-mediated apoptosis. 13, 14 Previous reports showed that increasing DR5 gene expression can increase TRAIL-induced apoptosis. [15] [16] [17] Thus, we examined whether CD154-DC can increase levels of apoptosis by inducing death receptors such as TRAIL-R1, TRAIL-R2 and Fas. OSC-70 cells co-cultured with CD154-DC were evaluated for the expression of TRAIL-R1, TRAIL-R2 and Fas. In contrast to OSC-70 cells co-cultured with LacZ-DC, OSC-70 cells co-cultured with CD154-DC expressed high levels of TRAIL-R2 (Figure 4) .
Human leukocyte antigen (HLA)-class I, HLA-class II and intercellular adhesion molecule 1 are necessary for recognition of tumor cells by immune effector cells. [18] [19] [20] [21] [22] Downregulation of these molecules was a frequent event observed in several tumors. 23, 24 To investigate whether the phenotype of the tumor cells could be altered following co-cultivation with CD154-DC, we measured surface levels of immune co-stimulatory molecules. Following co-cultivation with CD154-DC in transwell plates, HLA-class I, HLA-class II and CD54 levels expressed on OSC-70 cells were evaluated by flow cytometry. In contrast to controls, OSC-70 cells cocultured with CD154-DC expressed high levels of HLA-class I and CD54 (Figure 4) . Importantly, HLAclass II expression on OSC-70 cells, which is normally very low, was highly induced by co-cultivation with CD154-DC.
CD154-DC, but not LPS-or TNFa-DC, induced growth suppression of tumor cells
It has been shown that molecules in the TNF family or ligands of Toll-like receptors contribute to the maturation and activation of DC. We next examined the induction of growth suppression of OSC-70 by DCs with various stimuli. Compared with immature DC, the addition of TNF-a or LPS could upregulate the expression of CD80 as a maturation/activation marker of DC (MFI CD80: 58 vs 134 and 402; Figure 5a ). Adenovirus-mediated gene transfer of lacZ did not induce DC maturation, whereas CD154 could upregulate the CD80 expression (MFI CD80: 60 vs 293), indicating that DC stimulated with LPS (LPS-DC) could express significantly higher levels of CD80 than those stimulated with TNF-a or CD154. It is important that growth suppression of tumor cells were strongly induced only by CD154-DC but not by im-DC, TNFa-DC or LacZ-DC (Figure 5b ). In contrast to the phenotypic changes in DC, LPS-DC could inhibit tumor growth moderately. Conceivably, signal transduction Gene transfer of CD40-ligand to dendritic cells K Tomihara et al mediated by CD154 or LPS in DC might be distinct between phenotypic alterations in immune response and cytostatic activity against tumors.
IFN-g produced by CD154-DC mediated the growth suppression and TRAIL susceptibility of tumor cells
Recently, the susceptibility to TRAIL was shown to be induced by IFN-g. 25, 26 Stimulation with CD154 has also been shown to increase TNF-a-or FasL-mediated apoptosis of CD40-expressing tumor cells. 27, 28 Since OSC-70 cells express CD40 (Tomihara et al., unpublished observation), this may be a possible mechanism for the enhancement of TRAIL-mediated apoptosis. Thus, from cultures, we measured IFN-g, IL-12p70 and soluble CD154 levels by ELISA. As shown in Figure 6 , the IFN-g concentration was 11-fold higher in CD154-DC supernatants (18.38±0.73 ng per 10 6 cells per 48 h) than in LacZ-DC supernatants (1.67 ± 0.03 ng per 10 6 cells per 48 h). CD154 levels were 13-fold higher in CD154-DC supernatants (9.65 ± 0.41 ng per 10 6 cells per 48 h) as compared to the control (0.71 ± 0.54 ng per 10 6 cells per 48 h). Similarly, CD154-DC could produce large amount of IL-12p70 in the culture supernatant (2.22 ± 0.34 ng per 10 6 cells per 48 h). These data led us to believe that CD154-DC-secreted IFN-g, IL-12p70 or soluble CD154 might be responsible for augmentation of TRAILinduced apoptosis in the tumor cells co-cultured with CD154-DC.
To evaluate the contribution of these cytokines in tumor growth arrest and TRAIL susceptibility, we examined the growth of OSC-70 cells co-cultured with CD154-DC in the presence or absence of a neutralizing antibody to IFN-g (anti-IFN-g Ab) or CD154 (anti-CD154 Ab). Anti-IFN-g Ab, but not anti-CD154 Ab blocked CD154-DC-induced growth suppression of OSC-70 cells (data not shown). We next examined the TRAIL susceptibility of OSC-70 cells co-cultured with CD154-DC in the presence or absence of an anti-IFN-g Ab or an anti-CD154 Ab. Anti-IFN-g Ab blocked the TRAILinduced cell death of CD154-DC co-cultured OSC-70 cells partially, but significantly at all TRAIL concentrations tested ( Figure 7a ) (n ¼ 3, Po0.05 for all concentrations of TRAIL). In contrast, anti-CD154 Ab had no effect on TRAIL-induced cell death of CD154-DC co-cultured OSC-70 cells ( Figure 7b ).
We then examined whether cytostatic activity of CD154-DC could be replaced by the addition of recombinant human IFN-g (rhIFN-g). As represented in Figure 7c , growth inhibition of OSC-70 cells with 25% of CD154-DC supernatant containing IFN-g at 2750 pg ml À1 was definitely observed (34.7% vs control culture). In contrast, the addition of equal amounts of rhIFN-g (2750 pg ml
À1
) to medium or LacZ-DC supernatants partially inhibited tumor cell growth (65.1 or 75.3% vs control culture), indicating that additional rhIFN-g did not fully take the place of CD154-DC. In addition to above results, the upregulation of TRAIL susceptibility by co-cultivation with CD154-DC were also observed in CD40-negative tumor cells (data not shown). In preliminary data, we found that immunostimulatory cytokine IL-12p70 could not induce the tumor growth arrest and phenotypic alterations. Collectively, these results suggest that CD154-DC-derived IFN-g but not soluble CD154 nor IL-12p70, at least in part, mediates CD154-DC-mediated tumor growth suppression and susceptibility of apoptosis via TRAIL.
JAK-STAT signaling is an important pathway in the induction of several pro-apoptotic effects by IFNs. 29, 30 Moreover, sensitivity to TRAIL-induced apoptosis in tumor cells was regulated by altering the levels of TRAIL receptors, [15] [16] [17] and of anti-apoptotic molecules such as Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE) inhibitor protein (FLIP) 31 or death-associated protein-3 (DAP3). 32 Post-translational modification of anti-apoptotic molecules such as Akt also contribute to TRAIL-induced apoptosis. [33] [34] [35] [36] To investigate whether expression levels of molecules relating to TRAIL-mediated apoptosis were affected when OSC-70 cells were co-cultured with CD154-DC, we performed western blot analyses of STAT-1, Akt, Ser473-phosphorylated Akt, cFLIP and DAP3. As shown in Figure 7D , upregulation of STAT-1 and downregulation of Akt phosphorylation were observed in OSC-70 cells following co-cultivation with CD154-DC. The neutralizing anti-IFN-g Ab attenuated these changes. No remarkable Gene
In vivo efficacy of CD154-DC to treat established oral squamous cell carcinoma xenograft Based on the biological activity of CD154-DC in vitro, we evaluated the antitumor efficacy of CD154-DC treatment in OSC-70 xenografts. Athymic nude mice bearing subcutaneously (s.c.) OSC-70 were injected intratumor for once a week three times with CD154-DC, LacZ-DC or phosphate-buffered saline (PBS) and tumor growth was monitored for up to 30 days after the initial treatment. There was no significant effect on growth kinetics in tumors treated with LacZ-DC compared with control mice. In contrast to no therapeutic effect of LacZ-DC, a potent antitumor effect of CD154-DC became apparent 5 days after treatment, and this effect was sustained over the treatment (Figure 8 ). However, all mice treated with CD154-DC exhibited tumor regrowth after second or third treatment. Student's t-test analysis of the data of tumor volume (day 30) and tumor weight (day 35) revealed that the difference between the CD154-DCinjected and LacZ-DC-injected groups were significant (Po0.05). Collectively, these results indicated that CD154-DC exhibit potent antitumor property against tumor xenograft.
Discussion
Several reports have shown that adenovirus-mediated murine CD154 gene transduction to DC induce antitumor effect following generation of tumor-specific CTL. 37, 38 In the present study, we developed the modified adenovirus vectors encoding human CD154 gene to enable the superior gene transduction efficiency against DC and demonstrated that adenovirus-mediated transduction of the human CD154 gene to DC imparts a direct antitumor effect. By co-culturing in a transwell plate, we demonstrated that DC transduced with the CD154 gene (CD154-DC) suppressed growth of tumor cells without cell-to-cell contact. In addition to inhibiting tumor cell growth, TRAIL-mediated apoptosis was strongly induced in tumor cells following co-cultivation with CD154-DC. These results suggest that these cytostatic and cytotoxic effects toward tumor cells could be caused by soluble factors secreted by CD154-DC. DC are major producers of IFNs. Virally infected CD11c
À precursor DC release type 1 IFNs. 7, 8 It has also been reported that murine lymphoid DC stimulated with IL-12 or IL-18 can release IFN-g. 11 However, there is no report that human DC can produce this cytokine. In the present study, we have shown that CD154 transduction of human DC by adenovirus vectors can cause secretion of IFN-g. In addition, stimulation with recombinant CD154, TNF-a or LPS did not increase production of IFN-g and not inhibit tumor cell growth. These results suggest that it is important to stably express CD154 on cell membranes by gene transduction to stimulate DC IFN-g production.
Recently, it was recognized that IFNs are major modulators of death inducing stimuli such as FasL or TRAIL. It was reported that a combination of TRAIL receptor agonists and IFN-g treatment could induce apoptosis of TRAIL resistant tumor cells. 26 As shown in our data (Figure 6 ), CD154-DC secreted higher amounts of IFN-g compared with LacZ-DC. We also demonstrated that TRAIL-mediated cell death of OSC-70 cells following co-cultivation with CD154-DC was attenuated by blocking IFN-g with a specific antibody. IFNs are also known to exert several pro-apoptotic effects through the JAK-STAT signaling pathway. 29 More recently, it was found that type 1 IFNs stimulation induced a STAT-1-dependent TRAIL-mediated death signaling pathway. 30 In accordance with this data, we demonstrated that expression of STAT-1 protein was increased in OSC-70 cells following co-cultivation with CD154-DC. Further, this increase could be attenuated by blocking IFN-g with a specific antibody. These data suggest that TRAIL-induced apoptosis of OSC-70 cells following co-cultivation with CD154-DC could be upregulated by 5 dendritic cells per ml were determined by ELISA. In addition to Adv-infected-DC, supernatants of DC treated with recombinant tumor necrosis factor (TNF)-a (100 ng ml À1 ) or CD154 (100 ng ml À1 ) were also measured. One of data in two independent experiments was represented.
Gene transfer of CD40-ligand to dendritic cells K Tomihara et al CD154-DC-derived IFN-g. However, the addition of equal amounts of recombinant IFN-g to LacZ-DC supernatants was not fully replaced in the tumor cell growth arrest induced by CD154-DC (Figure 7c ). These data indicate that CD154-DC may produce other candidate factors for modulating tumor cell growth. We measured the levels of two other potential contributors. First, type 1 IFNs (a2b and b) were undetectable in supernatants of both LacZ-DC and CD154-DC cultures. The second potential contributor, CD154, however, was increased in the culture supernatant of CD154-DC ( Figure 6 ). In support of this notion, stimulation of CD40 positive tumor cells with CD154 suppressed tumor growth, increased chemotherapy sensitivity and enhanced apoptosis by apoptosis inducing stimuli such as TNF-a or FasL. 27, 28 While the CD154 detected in the culture supernatant may be a soluble form (sCD154) cleaved from CD154-DC, it is not clear whether it has the same functional activity as recombinant CD154 or as cells expressing CD154 on their surfaces. However, OSC-70 cells express CD40, this may be a possible mechanism for the enhancement of TRAIL-mediated apoptosis. However, as shown in our data, upregulation of TRAIL susceptibility of OSC-70 cells following co-cultivation with CD154-DC could not be attenuated by using a neutralizing antibody to CD154 (Figure 7b ). In addition, CD154-DC also induced TRAIL susceptibility on CD40-negative tumor cells (data not shown). Thus, it is unlikely that sCD154 contributes to the TRAIL susceptibility of tumor cells. Immunostimulatory cytokine IL-12p70 was abundantly produced by CD154-DC compared with TNFa-DC or LPS-DC; however, we Several molecules have been reported to correlate with TRAIL susceptibility. FLIP is recognized to be one of these proteins. It was reported that high expression of FLIP correlated to TRAIL-resistant melanomas. 31 More recently, it was reported that DAP3, a GTP-binding protein that binds directly to the death domain of TRAIL receptors, is required for TRAIL-induced apoptosis. DAP3 also associates with the pro-caspase-8 binding adapter protein Fas-associated death domain (FADD) and links FADD to the TRAIL receptors DR4 and DR5. 32 Resistance to TRAIL-mediated apoptosis has been attributed to differential expression of TRAIL receptors (DRs). [15] [16] [17] OSC-70 cells following co-cultivation with CD154-DC upregulated TRAIL-R2 expression. However, western blot analysis for cFLIP and DAP3 revealed no remarkable changes in expression levels following co-cultivation with CD154-DC. Thus, the secretion of soluble factors by CD154-DC did not affect the expression of these proteins in OSC-70 cells. Further study is needed in order to shed light on the mechanism involved. Other possibilities include a change in the phosphorylation state or intracellular localization of these molecules and/or the involvement of anti-apoptotic molecules other than those already studied. In addition to alterations of these molecules, constitutive phosphorylation of Akt may contribute to the resistance of TRAIL-induced cell death. Akt is a Ser/Thr protein kinase activated in many cancers. It has been reported that activation of Akt promotes tumor cell growth, inhibition of apoptosis and drug resistance. 39, 40 Several cancer cells with high levels of Akt activity were resistant to TRAIL-induced apoptosis. [33] [34] [35] [36] As shown in our data (Figure 7d ), OSC-70 cells co-cultured with CD154-DC downregulated Akt phosphorylation. Therefore, disruption of Akt signaling may be an effective way to treat many cancers.
In this study, we have demonstrated that human DC infected with Adv-CD154 (CD154-DC) suppressed tumor cell growth and enhanced TRAIL susceptibility. As expected, CD154-DC exhibited potent antitumor property in OSC-70-bearing mice. We also observed a therapeutic effect of CD154-DC against human renal carcinoma ACHN xenograft (data not shown). Considered together, CD154-DC could be a useful tool for cancer therapy; however, it would probably be most effective in combination with recombinant TRAIL or an agonistic monoclonal antibody specific for TRAIL receptors. A candidate source for TRAIL is the naturally occurring amount found on the cell surface of immune effector cells such as CTL and NK. Our results indicate that CD154-DC produce a large amount of IL-12, which is also a potent soluble factor to activate T helper-1, CTL and NK cells. In addition, high levels of IFN-g were reproducibly secreted by CD154-DC. Smyth et al. 41 previously demonstrated that TRAIL induction on NK cells plays a critical role in IFN-g-mediated antimetastatic effects of IL-12. We also found that culturing the NK cells with CD154-DC significantly induced the expression of TRAIL on the cell surface (unpublished results). We are now investigating the antitumor effect of NK cells expressing TRAIL in combination with CD154L-DC in vitro and in vivo. In conclusion, DC transfected with stable CD154 may be more efficient at inducing both direct cytostatic and apoptosis-inducing effects toward tumor cells as well as indirect immune responses mediated by NK and CTLs. The next step of our research is to verify the antitumor efficacy in immunocompetent animal model. Thus, this approach may be a viable immune gene therapy for cancer patients.
Materials and methods
Preparation of DC
Human peripheral blood mononuclear cells were donated from healthy donors. In brief, non-adherent cells were depleted, and adherent cells were cultured in complete RPMI-1640 medium (containing 1 mM sodium pyruvate, antibiotics and 10% fetal calf serum (FCS)) supplemented with recombinant human granulocyte macrophage-colony stimulating factor and IL-4 (Osteogenetics GmbH, Wuerzburg, Germany) at a concentration of 50 ng ml À1 for 7 days.
Tumor cells
The human oral squamous cell carcinoma cell line, OSC-70, established from a metastatic oral squamous carcinoma as described previously 42 was maintained in complete RPMI-1640 medium.
Culture experiments
To co-cultivate OSC-70 cells with DC, we used a dualchamber transwell plate separated by a 0.4-mm pore size Gene transfer of CD40-ligand to dendritic cells K Tomihara et al semi-permeable membrane (12-well plate, Corning Inc., Corning, NY, USA).
Adenovirus
All the recombinant adenoviral vectors used in this study were based on the E1-and E3-deleted serotype 5 adenovirus with a modified fiber F/RGD, harboring an integrin-binding RGD-motif within the HI loop of its knob protein. 43 In the first step, a 14 896-bp EcoRI fragment (including the right side of the adenoviral genome) of pWEAxKM-F/RGD 43 was joined with a 24 505-bp EcoRI fragment (including the left side of the adenoviral genome) of pL RI , 44 generating the cosmid vector pWEAx-F/RGD.
Human CD154 cDNA was cloned by RT-PCR using total RNA extracted from activated human T cells of healthy donors. The human CD154 primer sequences were: Forward, 5 0 -CGG AAT TCA GCA TGA TCG AAA CAT ACA ACC AAA C-3 0 Reverse, 5 0 -CGG GAT CCT CAG AGT TTG AGT AAG CCA AAG GAC G-3 0 . The human CD154 cDNA was inserted between the EcoRI and BglII sites in the pCAcc vector, and the resulting plasmid was designated pCAhCD154. Then, pCAhCD154 was digested with ClaI, and the CD154 expression unit was inserted into the ClaI site of pWEAx-F/RGD, resulting in the cosmid vectors pWEAxCAhCD154-F/RGD. To generate recombinant adenovirus, Pac I-digested cosmid was transfected into 293 cells with Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA, USA). Resulting plaques were isolated, and they were evaluated by restriction enzyme digestion of the viral genome. Similarly, AxCAZ3-F/RGD that carried lacZ as a reporter gene was generated. The resulting adenoviral vectors, AxCAhCD154-F/RGD (Adv-CD154) and AxCAZ3-F/RGD (Adv-LacZ) were amplified in 293 cells and purified by cesium chloride ultracentrifugation. 45 Purified viruses were dialyzed against PBS with 10% glycerol and stored at À70 1C until use. To determine the viral concentration (particle per ml), the viral solution was incubated in 0.1% sodium dodecyl sulfate (SDS) and its absorbance was measured at A 260 . 46 The concentration was defined as pt per ml ¼ A 260 Â (1.1 Â 10 12 ). Before use, contamination of the viral stocks with replication-competent viruses was ruled out by PCR analysis using primers specific for E1A and E1B. 47 Adenovirus infection DC were infected with adenovirus using 1000 pt per cell to achieve nearly 100% infection efficiency. After 48 h of adenovirus infection, DC were evaluated for maturation markers by flow cytometry. In all of the assays, DC were used 48 h post-infection.
Reagents and neutralizing antibodies
Recombinant TNF-a (rhTNF-a), IFN-g (rhIFN-g) and CD154 (rhCD154) proteins were purchased from PeproTech (London, UK), R&D systems (Minneapolis, MN, USA) and Alexis Corporation (San Diego, CA, USA), respectively. Monoclonal antibodies specific for human IFN-g (anti-IFN-g Ab) or CD154 (anti-CD154 Ab) were purchased from BD-PharMingen (San Diego, CA, USA).
Flow cytometry
Cells were washed and then suspended in staining media (PBS, 2% FCS, 0.05%. NaN 3 and 1 mg ml À1 propidium iodide (PI)) containing saturating amounts of fluorochrome-conjugated mAbs. After 30 min at 4 1C, the cells were washed with staining media and analyzed by flow cytometry using a FACS-Calibur (Becton Dickinson, San Jose, CA, USA). Dead cells staining with PI were excluded from the analysis. The relative expression of surface antigen is described as the mean fluorescence intensity ratio (mean fluorescence intensity ratio (MFIR)). MFIR equals the MFI of cells stained with a fluorochrome-conjugated antigen-specific mAb divided by the MFI of cells stained with a fluorochrome-conjugated isotype control mAb. Fluorescein (FITC)-conjugated mAbs specific for human CD54 were purchased from Caltag (Burlingame, CA, USA). Fluorescein (FITC)-conjugated mAb specific for human CD80, CD86, CD95, CD154 or HLA-DR, DP, DQ and phycoerythrin (PE)-conjugated mAb specific for HLA-ABC were obtained from BD-PharMingen. Fluorescein (FITC)-conjugated mAb specific for human TRAIL-R1 (DR4) or TRAIL-R2 (DR5) were obtained from Alexis. PE-conjugated mAb specific for human CD83 was purchased from Immunities (Marselle, France).
Cytokine ELISA
Supernatants of DC were collected 48 h after infection with Adv-LacZ or Adv-CD154. Cytokine levels were measured using ELISA kits specific for IFN-g (eBioscience, San Diego, CA, USA), IL-12p70 (R&D systems), CD154, IFN-a or IFN-b (PBL Biomedical Laboratories, Piscataway, NJ, USA) according to manufacturer's instructions at 450 nm.
Immunoblot analysis
Cells were lysed with 1 Â lysis buffer (10 mm Tris-HCl (pH 7.4), 1% SDS, 1 mm sodium orthovanadate). The protein content of the supernatants was determined using the DC protein assay kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. An equal volume of 2 Â Laemmli buffer was added to the supernatants and boiled for 5 min. Equal amounts of protein (30 mg) were separated using 5-20% gradient polyacrylamide gels and transferred onto nitrocellulose membranes. After blocking with 5% milk in Tris-buffered saline 10 mm Tris-HCl (pH 7.5), 150 mm sodium chloride, 0.05% Tween-20) the membranes were incubated with primary antibodies for 1 h at room temperature. Primary antibodies used included mouse anti-human STAT-1 monoclonal antibody (no. 9176; Cell Signaling Technology, Beverly, MA, USA), rabbit anti-human Akt polyclonal antibody (no 9272; Cell Signaling Technology), mouse anti-human phospho-Akt (Ser473), or mouse anti-b-actin monoclonal antibody (no. A-5441; Sigma, St Louis, CA, USA), rabbit anti-human-FLIPg/d polyclonal antibody (no. 343006, Calbiochem, Darmstadt, Germany) or mouse anti-human DAP3 monoclonal antibody (no. 9176; BD PharMingen, San Diego, CA, USA). After washing, the membranes were incubated for 1 h at room temperature with 30 ml (per 15 ml) of horseradish peroxidase-conjugated rabbit anti-mouse IgG+A+M (H+L) (no. 61-6420; Zymed Laboratories, San Francisco, CA, USA) or donkey anti-rabbit IgG, Gene transfer of CD40-ligand to dendritic cells K Tomihara et al peroxidase-linked species-specific F(ab')2 fragment (Amersham, Little Chalfont, UK). Detection was carried out by enhanced chemi-luminescence (Amersham) according to the manufacturer's instructions.
Assessment of cell viability
Cells were seeded into 96-well plates at 1.5 Â 10 4 cells per well 1 day prior to the experiment. Cells were treated with increasing concentrations (6.25, 12.5, 25, 50 and 100 ng ml
À1
) of recombinant TRAIL (R&D). To measure the viability of adherent cells, tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate) premix (Takara Bio, Otsu, Shiga, Japan) was added to each well. The cleavage of WST-1 into formazan by metabolically active cells was measured by scanning the plates at 450 and 650 nm reference wavelengths in a microtiter plate reader.
Assessment of apoptosis
OSC-70 cells co-cultured in transwell dishes with DC were replated onto 60 mm dishes. After 24 h, OSC-70 cells were treated with recombinant human TRAIL at a concentration of 12.5 ng ml
À1
. After another 24 h, DNA fragments in apoptotic cells were detected using the APO-BRDU kit (BD PharMingen) according to the manufacturer's instructions. The kit is a two color TUNEL assay for labeling DNA breaks by Br-dUTP plus FITC-anti-BrdU antibody and total cellular DNA by PI.
Xenograft studies
Female athymic KSN-slc nude mice, 6-8 weeks of age, were purchased from Japan SLC Inc. (Shizuoka, Japan) and housed at the Sapporo Medical University animal facility. This animal studies were approved by the Animal Subject Committee (protocol no. 07-022) and the Biosafety Committee (approval no. Sapmed-1043) of the Sapporo Medical University and were performed in accordance with institutional guidelines.
OSC-70 cells in cultures were trypsinized, washed and resuspended with PBS. The viable OSC-70 cells (1 Â 10 6 ) were transplanted s.c. into the left flank of the athymic mice. After 4 days, mice were randomized into the three groups: (1) PBS as control, (2) LacZ-DC and (3) CD154-DC (n ¼ 5 in each group), and treatment was initiated (day 0). LacZ-DC or CD154 (5 Â 10 5 ) was injected i.t. once a week for 3 weeks and mice were monitored twice weekly until day 35. Tumor diameters were serially measured with digital calipers, and the tumor volume was estimated using the following formula: tumor volume (mm 3 ) ¼ (long diameter) Â (short diameter) 2 Â 0.4. A total of 39 days after tumor inoculation, all mice were euthanized and tumor tissues surgically obtained were weighed.
Statistical analysis
The statistical significance of the data was analyzed using a Student's t-test. A P-value of less than 0.05 was considered to be significant.
